DR. REDDY'S LABORATORIES-ADR (RDY) Stock News
NYSE:RDY - New York Stock Exchange, Inc. - US2561352038 - ADR - Currency: USD
RDY Latest News, Press Relases and Analysis
Henlius und Dr. Reddy's unterzeichnen Lizenzvertrag für HLX15 (Daratumumab-Biosimilar) zur Expansion in Europa und den USA
/PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) meldete heute die Unterzeichnung einer Lizenzvereinbarung mit Dr. Reddy's Laboratories SA, einer...
Henlius y Dr. Reddy's firman un acuerdo de licencia para la expansión de HLX15 en Europa y EE.UU.
/PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) anunció hoy que ha firmado un acuerdo de licencia con Dr. Reddy's Laboratories SA, filial de propiedad...
Henlius et Dr. Reddy's signent un accord de licence pour l'expansion de HLX15 (biosimilaire expérimental du daratumumab) en Europe et aux États-Unis.
/PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) a annoncé aujourd'hui qu'elle avait conclu un accord de licence avec Dr. Reddy's Laboratories SA,...
Dr. Reddy's Stock Hit All-Time High Last Month. Ready To Climb Again?
Dr. Reddy's Labs sees its Relative Strength Rating enter the 80-plus level.
Mentions: COLL
Dr. Reddy's Labs Stock Sees Improved Technical Strength
On Friday, Dr. Reddy's Labs ADR stock earned an upgrade to its Relative Strength (RS) Rating, from 66 to 76.
Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.
/PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) today announced it has entered into a license agreement with Dr. Reddy's Laboratories SA, wholly-owned...
Dr Reddy's Laboratories Q3 Earnings: Double-Digit Growth Aided By Newly Acquired Nicotine Replacement Business
Dr. Reddy's Q3 FY2025 revenue reached $977 million, up 16%, with $165M net income. Growth fueled by NRT portfolio and global generics expansion.
Mentions: HLN
Dr. Reddy’s Q3 & 9MFY25 Financial Results
Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US Market
Dr. Reddy’s Q2 & H1FY25 Financial Results
Dr. Reddy's Named by Science Magazine in Top 20 Global Pharma Employers List for Third Consecutive Year
Dr. Reddy’s Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness Month
Aurigene Oncology Limited Announces Promising Results of Phase 1 Study for India’s First Trial for Novel Autologous CAR-T Cell Therapy for Multiple Myeloma
Dr. Reddy’s signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries
Organon Stock Sees Relative Strength Rating Rise To 91
On Tuesday, Organon[ stock hit an key technical milestone, seeing its Relative Strength Rating jump to 91, up from 88 the day before.
Organon Stock Earns Relative Strength Rating Upgrade; Hits Key Threshold
On Tuesday, generic drug maker Organon stock had its Relative Strength (RS) Rating upgraded to 83, up from 78 a day earlier.
Dr. Reddy’s Laboratories, Aurigene Pharmaceutical Services, and Kainomyx Announce Potential Partnership for Joint Development of Affordable Anti-Malarial Drug
Dr. Reddy’s Receives Positive CHMP Opinion From European Medicines Agency for Its Proposed Rituximab Biosimilar
Dr. Reddy’s Q1FY25 Financial Results
Aurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing Capabilities
Dr. Reddy’s to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare Business
Mentions: HLN
India Stocks Rally On Modi Election Wave. This Indian Bank Stock Hits High.
Exit polls forecast a landslide win and third consecutive term for Prime Minister Narendra Modi in India's general elections.
Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America
Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK
Mentions: ALVO
